Table 1 Clinical characteristics of individuals recruited and of plasma and PBMCs analysed after quality control of samples
From: Circulating miR-16-5p, miR-92a-3p and miR-451a are biomarkers of lung cancer in Tunisian patients
Variable | Cohort of patients recruited | Plasma samples analysed (after passing quality control) | PBMCs analysed (after passing quality control) | |||||
|---|---|---|---|---|---|---|---|---|
Healthy control individuals n = 25 | Lung cancer patients | Healthy control individuals n = 24 | Lung cancer patients | Healthy control individuals n = 17 | Lung cancer patients untreated n = 29 | |||
Untreated n = 29 | Treated with chemotherapy n = 47 | Untreated n = 29 | Treated with chemotherapy n = 37 | |||||
Gender | ||||||||
Male | 21 | 25 | 39 | 21 | 25 | 33 | 17 | 25 |
Female | 4 | 4 | 8 | 3 | 4 | 4 | 0 | 4 |
Age | ||||||||
≥ 60 | 0 | 7 | 26 | 0 | 7 | 17 | 0 | 7 |
< 60 | 25 | 22 | 21 | 24 | 22 | 20 | 17 | 22 |
Tumour subtype | ||||||||
NSCLC | 29 | 46 | 29 | 36 | 29 | |||
SCLC | 0 | 1 | 0 | 1 | 0 | |||
TNM stage | ||||||||
Stage I | 0 | 2 | 0 | 0 | 0 | |||
Stage III-IV | 29 | 45 | 29 | 37 | 29 | |||
Chemo-therapy regimen | ||||||||
Cisplatine + Gemzar® | 18 | 14 | ||||||
Cisplatine + Navelbine® | 23 | 20 | ||||||
Cisplatine + Taxol® | 6 | 3 | ||||||